About: Molecular Pathology Economics 101: an Overview of Molecular Diagnostics Coding, Coverage and Reimbursement

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Molecular Pathology Economics 101: an Overview of Molecular Diagnostics Coding, Coverage and Reimbursement Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Molecular Pathology Economics 101: an Overview of Molecular Diagnostics Coding, Coverage and Reimbursement
Creator	Harrington, Amanda Dien Bard, Jennifer Bossler, Aaron Aisner, Dara Burke, Tara Caughron, Samuel Hiemenz, Matthew Joseph, Loren Patel, Jay Rosca, Oana Sireci, Anthony Thibault-Sennett, Sarah An, Sireci Emmadi, Rajyasree Gagan, Jeffrey Hagelstrom, Tanner Hsaio, Susan Hutchinson, Lloyd Jl, Patel Mc, Hiemenz Monzon, Federico Novak, Jan Oana, ¶ǁ Pratt, Victoria Priore, Salvatore Rajadhyaksha, Aparna Rosca, C Sepulveda, Antonia Stein, Ester Tynan, Katherine
Source	PMC
abstract	Widespread indications for use of molecular diagnostics in various aspects of clinical medicine have driven proliferation of testing. The rapid adoption and continuous technological evolution of molecular diagnostics have often strained the development and maintenance of a functional underlying framework of coding, coverage, and reimbursement policies, thereby presenting challenges to various stakeholders including molecular professionals, payers, and patients. A multidisciplinary working group convened by the Association for Molecular Pathology Economic Affairs Committee was tasked to describe the complex landscape of molecular pathology economics and highlight opportunities for member engagement. In this manuscript, on the basis of review and synthesis of government regulations and procedures, published payer policy documents, peer-reviewed literature, and expert consensus, the Working Group navigates the ecosystem of molecular pathology economics in terms of stakeholders, coding systems and processes, coverage policy determination, and pricing mechanisms. The composition and interrelatedness of various working groups and committees are emphasized in order to highlight the functional underpinnings of the system. Molecular professionals must be conversant in the language and complex inner workings of molecular pathology economics in order to lead successful, viable laboratories and advocate effectively for policy development on their behalf. This overview is provided to be a resource to molecular professionals as they navigate the reimbursement landscape.
has issue date	2020-06-03(xsd:dateTime)
bibo:doi	10.1016/j.jmoldx.2020.05.008
has license	no-cc
sha1sum (hex)	afe5cf29d3ae0a9bd2d909df1faf8a8aedb7fa75
schema:url	https://doi.org/10.1016/j.jmoldx.2020.05.008
resource representing a document's title	Molecular Pathology Economics 101: an Overview of Molecular Diagnostics Coding, Coverage and Reimbursement
has PubMed Central identifier	PMC7267794
schema:publication	J Mol Diagn
resource representing a document's body	covid:afe5cf29d3ae0a9bd2d909df1faf8a8aedb7fa75#body_text
is schema:about of	named entity 'highlight' named entity 'payers' named entity 'composition' named entity 'payer' named entity 'stakeholders' named entity 'member' named entity 'terms' named entity 'indications' named entity 'multidisciplinary' named entity 'Overview' named entity 'pricing mechanisms' named entity 'government regulations' named entity 'determination' named entity 'coverage' named entity 'adoption' named entity 'Molecular Pathology' named entity 'landscape' named entity 'policy' named entity 'molecular diagnostics' named entity 'presenting' named entity 'peer-reviewed' named entity 'Molecular Pathology' named entity 'Diagnostics' named entity 'Molecular Diagnostics' named entity 'medical costs' named entity 'Category III' named entity 'Medicaid' named entity 'molecular pathology' named entity 'genome' named entity 'pathology services' named entity 'Medicare' named entity 'HCPCS' named entity 'Medicare' named entity 'oncology' named entity 'durable medical equipment' named entity 'Type 1' named entity 'HCPCS' named entity 'Type 2' named entity 'laboratory medicine' named entity 'molecular testing' named entity 'molecular pathology' named entity 'CMS' named entity 'molecular pathology' named entity 'molecular testing' named entity 'NCD' named entity 'CMS' named entity 'health insurers' named entity 'CMS' named entity 'CPT' named entity 'Medicare' named entity 'DNA extraction' named entity 'Medicare' named entity 'Category III' named entity 'Category II'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software